Get all your news in one place.
100's of premium titles.
One app.
Start reading
Benzinga
Benzinga
Business
Benzinga Insights

UNBELIEVABLE: Looking into cara therapeutics s return on capital employed - Caught on Camera

Benzinga Pro data, Cara Therapeutics (NASDAQ:CARA) reported Q4 sales of $821.00 thousand. Earnings fell to a loss of $33.38 million, resulting in a 3195.36% decrease from last quarter. In Q3, Cara Therapeutics brought in $20.27 million in sales but lost $1.01 million in earnings.

What Is Return On Capital Employed?

Sign up to read this article
Read news from 100's of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member? Sign in here
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.